Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stake Lessened by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 80.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 75,500 shares of the company's stock after selling 319,533 shares during the period. JPMorgan Chase & Co. owned 0.08% of Aquestive Therapeutics worth $269,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Harvey Capital Management Inc. lifted its holdings in shares of Aquestive Therapeutics by 1,419.3% during the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after acquiring an additional 249,790 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock worth $15,474,000 after buying an additional 82,958 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Aquestive Therapeutics in the fourth quarter valued at about $498,000. Barclays PLC raised its holdings in shares of Aquestive Therapeutics by 285.4% during the 3rd quarter. Barclays PLC now owns 99,312 shares of the company's stock valued at $495,000 after buying an additional 73,542 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Aquestive Therapeutics by 28.7% in the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock worth $117,000 after acquiring an additional 7,347 shares during the period. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded down $0.14 during trading on Tuesday, reaching $2.69. 1,058,901 shares of the company's stock traded hands, compared to its average volume of 1,467,408. The company has a 50 day moving average of $2.78 and a 200-day moving average of $3.52. Aquestive Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $5.80. The stock has a market capitalization of $267.17 million, a P/E ratio of -5.98 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million. Equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AQST. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Lake Street Capital reduced their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Finally, Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Aquestive Therapeutics has an average rating of "Buy" and a consensus target price of $10.67.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.